Physician profile
Michael Resnikoff
NPI 1689690786
$9,197.12
in general payments reported to CMS, 2019-2025
12 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $324 · 2021: $5,612 · 2022: $421 · 2023: $420 · 2024: $376 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439 · Travel and Lodging: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.90 |
| Travel and Lodging | $728.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $7,595.94 | 2019-2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore Tag Conformable Thoracic Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control |
| Silk Road Medical, INC. | $991.30 | 2021 | |
| Shockwave Medical, INC | $193.77 | 2025 | |
| Bard Peripheral Vascular, INC. | $145.22 | 2019-2021 | |
| Smith+Nephew, INC. | $66.37 | 2019-2024 | Renasys Go V2 Home |
| Acera Surgical, INC. | $45.16 | 2025 | Restrata Wound Matrix |
| Medtronic Vascular, INC. | $41.13 | 2020 | |
| Mozarc Medical US LLC | $34.71 | 2023 | Argyle |
| Advanced Oxygen Therapy INC. | $24.24 | 2022 | |
| Boston Scientific Corporation | $23.99 | 2022 | |
| Next Science LLC | $19.72 | 2022 | |
| Polarityte, INC. | $15.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Resnikoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.